We will help Chinese pharmaceutical companies’ generic drug, novel drug, and biological drug companies define EU market potential by identifying market position and market capability of providing the quickest returns. We will help you assess EU market attractiveness and establish EU market entry priorities according to the economic and socio-political factors affecting EU healthcare market, local regulatory requirements, distribution channels, partner selection and competition. With in-depth research, we will be able to develop, recommend and implement EU healthcare market entry strategies to meet client’s objectives.

Our services are specialised in:
  • Market Opportunity Assessment and Market research
  • Market Entry Strategy
  • Strategy Business Development
      > Partnership selection and evolution
      > Distributor and channel management